Subgroup analyses by cancer type showed that WT1 positive expression had an unfavorable impact on OS for patients with ovarian cancer (metaHR = 1.57, 95%CI = 1.10–2.24), endometrial cancer (metaHR = 1.96, 95%CI = 1.04–3.72) and non-carcinoma malignancies (metaHR = 1.59, 95%CI = 1.07–2.37) (Table 2). Here, WT1 is linked to cancer.